Product Datasheet

Sevabertinib

Catalog No. **BP-04435** · CAS **2521285-05-0** · Form **free base** · Physical state **solid** · Color **Light yellow to yellow** · Version **1.0** · Revision **2026-11-12**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target	Research area
EGFR	**Cancer**

Molecular formula	$C_{24}H_{25}ClN_4O_5$
Molecular weight	**484.9320**

STRUCTURE



DESCRIPTION

Sevabertinib (BAY 2927088) is an orally active and reversible dual EGFR-HER2 inhibitor (IC50 <0.5 nM for wild-type HER2, HER2 A775insYVMA, wild-type EGFR, and EGFR D770_N771insSVD). Sevabertinib has anticancer activity against lung cancer.

BIOLOGICAL ACTIVITY

Sevabertinib exhibits an IC50 of <0.5 nM against wild-type HER2, HER2 A775insYVMA, wild-type EGFR, and EGFR D770_N771insSVD at a physiological ATP concentration of 2 mM, and shows significantly reduced activity against HER4 (IC50 = 13.9 nM)

Sevabertinib potently inhibits the proliferation of isogenic Ba/F3 cells ectopically expressing HER2 exon 20 insertions, activating HER2 point mutations, or putative secondary acquired resistance mutations (T798M, T798I, C805S)

Sevabertinib potently inhibits the proliferation of two lung cancer cell lines: NCI-H1781 (harboring HER2 exon 20 insertion mutations A775insV and G776C) with an IC50 of 19.7 nM, and NCI-H2170 (harboring wild-type ERBB2 amplification) with an IC50 of 16.7 nM

SOLUBILITY

DMSO

In vitro	DMSO : 50 mg/mL

REFERENCES

[1]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 38, No. 2, 2024.

[2]. Siegel F, et al. Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer Discov. 2025 Oct 15.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com
BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.
Lot CoA and SDS are separate documents.